Novartis’ Cosentyx currently leads a crop of immunology meds from a who’s who of Big Pharma. And the company intends to keep it that way.
J&J dropped a lawsuit accusing Samsung Bioepis of infringing patents on Remicade, a $5 billion med that now faces biosimilar rivals.
In the ongoing saga of Outcome Health, a judge yesterday denied a request by investors to freeze part of its funding.
With time running short, EU members have been asked to set aside parochial interests in their pick for a new city to host the EMA.
Pfizer bowed out of a troubled joint venture with China's Hisun Pharma, which sells branded generic drugs in China.
Pfizer now has a chief operating officer and, potentially, a successor to CEO Ian Read: Albert Bourla, who now heads its Innovative Health unit.
President Donald Trump tweeted his nomination for ex-Eli Lilly executive Alex Azar as HHS secretary Monday morning.
While multiple analysts have suggested Pfizer bulk up in immuno-oncology, BMO's Alex Arfaei has a different idea.
FDA Commissioner Scott Gottlieb has unveiled yet another move to step up competition in the generics business.
Takeda, along with Lundbeck and Advocate Health Care, will study an app to track and measure patients’ experience on antidepressant therapies.